Print Page | Contact Us | Report Abuse | Sign In | Join
Detroit Diabetes
Share |

Integrating GLP-1 Inhibitors into a Comprehensive Diabetes Care Management Regimen –
The Incretin Experience 

This enduring activity features video and audio recording from the 2015 National Medical Association Scientific Assembly, Family Medicine Section held August 3rd in Detroit, Michigan. This activity is intended for primary care and family medicine physicians, endocrinologists, internists, nurse practitioners, and other healthcare professionals interested in diabetes. 

Gap/Needs Assessment: 
African American patients are more likely than white patients to have diabetes.  The risk of diabetes is 77% higher among African Americans than among non-Hispanic white Americans.  The rates of diagnosis of diabetes in non-Hispanic African Americans is 18.7% compared to 7.1% of non-Hispanic white Americans. That is 4.9 million African American adults with diagnosed or undiagnosed diabetes.  In 2006, African American men were 2.2 times more likely to start treatment for ESRD related to diabetes than non-Hispanic white men.  In the same year, African Americans with diabetes were 1.5 times more likely to be hospitalized and 2.3 times more likely to die from diabetes than non-Hispanic whites.  African Americans are almost 50% more likely to develop diabetic retinopathy than non-Hispanic whites. 

Learning Objectives:
Upon completion of this activity, participants should be able to: 

1. Summarize the efficacy, safety, and tolerability of GLP-1 agonists. 
2. Identify patients who would benefit from GLP-1 agonist therapy and those for whom it may not be appropriate.
3. Describe in patient-appropriate terms how GLP-1 agonists can improve glycemic control. 
4. Compare and contrast GLP-1 agonists, other incretin-based therapies, and traditional oral agents. 
5. Develop evidence-based treatment plans to incorporate incretin therapies in combination with oral agents and insulin for optimal glycemic control. 

Faculty Disclosures:
The following speakers/planners have indicated relationships with commercial interests: 

Morris L. Brown, M.D.
Consulting/Speakers’ Bureau
Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo NordiskJames

R. Gavin III, M.D., Ph.D.
Speakers BureauAstra
Zeneca, Boehringer Ingelheim, Eli Lilly


The following speakers/planners have indicated no relevant relationships with commercial interests: 

Warren A. Jones, M.D.
Kwabena Adubofour, M.D.

Acknowledgement of Commercial Support:
This activity was supported in part by educational grants from Janssen, Merck Sharp & Dohme Corp, and Novo Nordisk.


Session One

diabetes session 1 

Session Two

diabetes session 2


Course Syllabus

integrating glp 1


Expires November 1, 2016

National Medical Association | 8403 Colesville Road, Suite 820, Silver Spring, MD 20910 | 202-347-1895